IL6 and asthma: Given this association with increased non-type 2 pathways such as IL-6, future analyses should consider its overlap within type 2 asthma patients and immune pathway contributions because assessment of levels of type 2 biomarkers and non-type 2 biomarkers may aid in identifying overlapping asthma endotypes and potential responsiveness to treatment in patients with persistent severe asthma [8, 35].